Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.28 USD
Change Today -0.04 / -0.93%
Volume 5.8K
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

capricor therapeutics inc (CAPR) Snapshot

Open
$4.30
Previous Close
$4.32
Day High
$4.45
Day Low
$4.26
52 Week High
03/19/15 - $10.68
52 Week Low
01/8/15 - $3.05
Market Cap
69.6M
Average Volume 10 Days
23.2K
EPS TTM
$-0.63
Shares Outstanding
16.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CAPRICOR THERAPEUTICS INC (CAPR)

Related News

No related news articles were found.

capricor therapeutics inc (CAPR) Related Businessweek News

No Related Businessweek News Found

capricor therapeutics inc (CAPR) Details

Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of novel therapeutics to prevent and treat cardiovascular diseases. Its lead product candidates include CAP-1002 and Cenderitide. The company was founded in 2005 and is based in Beverly Hills, California.

28 Employees
Last Reported Date: 03/30/15
Founded in 2005

capricor therapeutics inc (CAPR) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $232.9K
Executive Vice President, General Counsel and...
Total Annual Compensation: $243.8K
Compensation as of Fiscal Year 2014.

capricor therapeutics inc (CAPR) Key Developments

Capricor Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Capricor Therapeutics, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's total income was $1.3 million compared with $1.0 million a year ago. Loss from operations was $3.1 million compared with $1.5 million a year ago. Net loss was $3.1 million or $0.19 per basic and diluted share compared with $1.5 million or $0.13 per basic and diluted share a year ago. For the six months, the company's total income was $3.1 million compared with $2.1 million a year ago. Loss from operations was $6.5 million compared with $2.7 million a year ago. Net loss was $6.6 million or $0.42 per basic and diluted share compared with $2.7 million or $0.23 per basic and diluted share a year ago.

Capricor Therapeutics, Inc., Q2 2015 Earnings Call, Aug 13, 2015

Capricor Therapeutics, Inc., Q2 2015 Earnings Call, Aug 13, 2015

Capricor Therapeutics Appoints Deborah Ascheim as Chief Medical Officer

Capricor Therapeutics, Inc. announced the appointment of Deborah D. Ascheim, M.D., to the position of Chief Medical Officer. Dr. Ascheim, a heart failure cardiologist, has significant experience directing national and international clinical trials, funded by both the NIH and industry sponsors. She was most recently Professor of Health Policy and Medicine and was the director of the International Center for Health Outcomes and Innovation Research's Clinical Trial Unit at the Icahn School of Medicine at Mount Sinai in New York. Prior to her tenure at Mount Sinai, Dr. Ascheim was on faculty in the Department of Medicine and division of Cardiology at the College of Physicians & Surgeons at Columbia University. While at Mount Sinai and Columbia, she served as either principal investigator or co-principal investigator for numerous high impact cardiovascular trials, including the NIH supported Cardiothoracic Surgical trials Network data coordinating center. She has been the principal investigator of an NIH supported trial of stem cells in LVAD patients, as well as an NIH CTRIP grant to evaluate targeted gene therapy for the treatment of heart failure.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CAPR:US $4.28 USD -0.04

CAPR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CAPR.
View Industry Companies
 

Industry Analysis

CAPR

Industry Average

Valuation CAPR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.0x
Price/Book 15.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAPRICOR THERAPEUTICS INC, please visit www.capricor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.